Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, April 2014

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 134 followers.

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic ... http://t.co/UwPIgS8Tr3

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic ... http://t.co/PFnK5oWr5H